Milestone Pharmaceuticals Inc.
MIST | 3/27/2025 | etripamil | PSVT | source |
Novavax, Inc.
NVAX | 4/1/2025 | NVX-CoV2601 | COVID-19 | source |
Royalty Pharma plc
RPRX | 4/1/2025 | cabozantinib | advanced neuroendocrine tumors | source |
Exelixis, Inc.
EXEL | 4/3/2025 | Cabometyx | previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated pnet and epnet | source |
Bristol-Myers Squibb Company
BMY | 4/21/2025 | Opdivo + Yervoy | HCC | source |
Abeona Therapeutics Inc.
ABEO | 4/29/2025 | PZ-CEL | RDEB | source |
Arcutis Biotherapeutics, Inc.
ARQT | 5/1/2025 | zoryve foam | scalp and body psoriasis | source |
UroGen Pharma Ltd.
URGN | 6/13/2025 | UGN-102 | low-grade upper tract urothelial cancer | source |
KalVista Pharmaceuticals, Inc.
KALV | 6/17/2025 | sebetralstat | hereditary angioedema (HAE) | source |
Unicycive Therapeutics, Inc.
UNCY | 6/28/2025 | oxylanthanum carbonate (olc) | hyperphosphatemia in patients with chronic kidney disease (ckd) on dialysis | source |
Ionis Pharmaceuticals, Inc.
IONS | 8/21/2025 | donidalorsen | hereditary angioedema | source |